CYPHERPUNK TECHNOLOGIES INC. Operating Income
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Operating Income of -$4.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for the quarter ending 2026-06-30 was -$4.69M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for the quarter ending 2026-03-31 was -$4.82M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for the quarter ending 2025-12-31 was -$5.10M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for the quarter ending 2025-09-30 was -$3.17M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for fiscal 2025 was -$41.07M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for fiscal 2024 was -$70.06M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for fiscal 2023 was -$87.04M.
- CYPHERPUNK TECHNOLOGIES INC. operating income (loss) for fiscal 2022 was -$56.76M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.69M 10-Q · filed 2026-08-12 | -$9.51M 10-Q · filed 2026-08-12 | -$14.61M derived: sum of 3 quarters · filed 2026-08-12 | -$17.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$4.82M 10-Q · filed 2026-05-14 | -$9.92M derived: sum of 2 quarters · filed 2026-05-14 | -$13.09M derived: sum of 3 quarters · filed 2026-05-14 | -$29.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$8.27M derived: sum of 2 quarters · filed 2026-03-16 | -$25.15M derived: sum of 3 quarters · filed 2026-08-12 | -$41.07M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$3.17M 10-Q · filed 2025-11-12 | -$20.05M derived: sum of 2 quarters · filed 2026-08-12 | -$35.96M 10-Q · filed 2025-11-12 | -$52.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$16.88M 10-Q · filed 2026-08-12 | -$32.80M 10-Q · filed 2026-08-12 | -$48.92M derived: sum of 3 quarters · filed 2026-08-12 | -$66.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$15.92M 10-Q · filed 2026-05-14 | -$32.04M derived: sum of 2 quarters · filed 2026-05-14 | -$49.90M derived: sum of 3 quarters · filed 2026-05-14 | -$71.15M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$16.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$33.98M derived: sum of 2 quarters · filed 2026-03-16 | -$55.23M derived: sum of 3 quarters · filed 2026-03-16 | -$70.06M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$17.86M 10-Q · filed 2025-11-12 | -$39.11M derived: sum of 2 quarters · filed 2025-11-12 | -$53.93M 10-Q · filed 2025-11-12 | -$68.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$21.25M 10-Q · filed 2025-08-14 | -$36.08M 10-Q · filed 2025-08-14 | -$50.90M derived: sum of 3 quarters · filed 2025-08-14 | -$65.73M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$14.82M 10-Q · filed 2025-05-13 | -$29.64M derived: sum of 2 quarters · filed 2025-05-13 | -$44.48M derived: sum of 3 quarters · filed 2025-05-13 | -$59.14M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$14.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$29.65M derived: sum of 2 quarters · filed 2025-03-26 | -$44.31M derived: sum of 3 quarters · filed 2025-03-26 | -$87.04M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$14.83M 10-Q · filed 2024-11-13 | -$29.50M derived: sum of 2 quarters · filed 2024-11-13 | -$72.22M 10-Q · filed 2024-11-13 | -$86.16M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$14.66M 10-Q · filed 2024-08-12 | -$57.39M 10-Q · filed 2024-08-12 | -$71.33M derived: sum of 3 quarters · filed 2024-08-12 | -$86.62M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$42.73M 10-Q · filed 2024-05-13 | -$56.67M derived: sum of 2 quarters · filed 2024-05-13 | -$71.96M derived: sum of 3 quarters · filed 2024-05-13 | -$88.86M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$29.23M derived: sum of 2 quarters · filed 2024-03-18 | -$46.13M derived: sum of 3 quarters · filed 2024-03-18 | -$56.76M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$15.29M 10-Q · filed 2023-11-13 | -$32.19M derived: sum of 2 quarters · filed 2023-11-13 | -$42.82M 10-Q · filed 2023-11-13 | -$53.31M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$16.90M 10-Q · filed 2023-08-14 | -$27.53M 10-Q · filed 2023-08-14 | -$38.02M derived: sum of 3 quarters · filed 2023-08-14 | -$50.16M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$10.63M 10-Q · filed 2023-05-15 | -$21.12M derived: sum of 2 quarters · filed 2023-05-15 | -$33.26M derived: sum of 3 quarters · filed 2023-05-15 | -$42.89M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$10.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$22.63M derived: sum of 2 quarters · filed 2023-03-24 | -$32.25M derived: sum of 3 quarters · filed 2023-03-24 | -$41.43M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$12.14M 10-Q · filed 2022-11-14 | -$21.77M derived: sum of 2 quarters · filed 2022-11-14 | -$30.94M 10-Q · filed 2022-11-14 | -$38.09M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$9.63M 10-Q · filed 2022-08-12 | -$18.80M 10-Q · filed 2022-08-12 | -$25.95M derived: sum of 3 quarters · filed 2022-08-12 | -$33.46M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$9.17M 10-Q · filed 2022-05-13 | -$16.33M derived: sum of 2 quarters · filed 2022-05-13 | -$23.83M derived: sum of 3 quarters · filed 2022-05-13 | -$31.33M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$14.66M derived: sum of 2 quarters · filed 2022-03-11 | -$22.16M derived: sum of 3 quarters · filed 2022-03-11 | -$28.54M 10-K · filed 2022-03-11 |
| 2020-09-30 | -$7.51M 10-Q · filed 2021-11-12 | -$15.00M derived: sum of 2 quarters · filed 2021-11-12 | -$21.39M 10-Q · filed 2021-11-12 | -$29.66M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$7.50M 10-Q · filed 2021-08-13 | -$13.88M 10-Q · filed 2021-08-13 | -$22.15M derived: sum of 3 quarters · filed 2021-08-13 | -$30.07M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | -$6.38M 10-Q · filed 2021-05-14 | -$14.65M derived: sum of 2 quarters · filed 2021-05-14 | -$22.58M derived: sum of 3 quarters · filed 2021-05-14 | -$31.04M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$16.20M derived: sum of 2 quarters · filed 2021-03-12 | -$24.66M derived: sum of 3 quarters · filed 2021-03-12 | -$33.45M 10-K · filed 2021-03-12 |
| 2019-09-30 | -$7.92M 10-Q · filed 2020-11-12 | -$16.38M derived: sum of 2 quarters · filed 2020-11-12 | -$25.18M 10-Q · filed 2020-11-12 | -$34.15M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$8.46M 10-Q · filed 2020-08-13 | -$17.26M 10-Q · filed 2020-08-13 | -$26.23M derived: sum of 3 quarters · filed 2020-08-13 | -$34.83M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$8.79M 10-Q · filed 2020-05-14 | -$17.77M derived: sum of 2 quarters · filed 2020-05-14 | -$26.36M derived: sum of 3 quarters · filed 2020-05-14 | -$33.20M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$17.57M derived: sum of 2 quarters · filed 2020-03-16 | -$24.41M derived: sum of 3 quarters · filed 2020-03-16 | -$30.75M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$8.60M 10-Q · filed 2019-11-14 | -$15.44M derived: sum of 2 quarters · filed 2019-11-14 | -$21.78M 10-Q · filed 2019-11-14 | -$28.33M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$6.84M 10-Q · filed 2019-08-09 | -$13.18M 10-Q · filed 2019-08-09 | -$19.73M derived: sum of 3 quarters · filed 2019-08-09 | -$28.31M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$6.34M 10-Q · filed 2019-05-15 | -$12.89M derived: sum of 2 quarters · filed 2019-05-15 | -$21.47M derived: sum of 3 quarters · filed 2019-05-15 | -$28.49M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$15.13M derived: sum of 2 quarters · filed 2019-04-01 | -$22.14M derived: sum of 3 quarters · filed 2019-04-01 | -$32.35M 10-K · filed 2019-04-01 |
| 2017-09-30 | -$8.58M 10-Q · filed 2018-11-09 | -$15.60M derived: sum of 2 quarters · filed 2018-11-09 | -$25.81M 10-Q · filed 2018-11-09 | -$33.74M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | -$7.02M 10-Q · filed 2018-08-08 | -$17.22M 10-Q · filed 2018-08-08 | -$25.16M derived: sum of 3 quarters · filed 2018-08-08 | -$32.19M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | -$10.21M 10-Q/A · filed 2018-08-08 | -$18.15M derived: sum of 2 quarters · filed 2018-08-08 | -$25.18M derived: sum of 3 quarters · filed 2018-08-08 | -$32.37M derived: sum of 4 quarters · filed 2018-08-08 |
| 2016-12-31 | -$7.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$14.97M derived: sum of 2 quarters · filed 2018-02-23 | -$22.16M derived: sum of 3 quarters · filed 2018-02-23 | -$27.30M 10-K · filed 2018-02-23 |
| 2016-09-30 | -$7.03M 10-Q · filed 2017-11-13 | -$14.22M derived: sum of 2 quarters · filed 2017-11-13 | -$19.36M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | -$7.19M 10-Q · filed 2017-08-11 | -$12.34M 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | -$5.14M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |